SAN FRANCISCO--(BUSINESS WIRE)--The results of a recent study presented yesterday at the American Heart Association Scientific Sessions 2012 conference in Los Angeles showed that a high-quality single-lead ECG can be quickly and easily recorded using an iPhone® with the AliveCor™ medical device and application to diagnose atrial fibrillation (AF). The study concluded that the mobile device could be an innovative approach to community screening to prevent stroke.
The study, “Validation of an iPhone ECG Application Suitable for Community Screening for Silent Atrial Fibrillation: A Novel Way to Prevent Stroke,” was presented by Dr. Jerrett Lau, from Sydney, Australia. The principal investigator was Dr. Ben Freedman, MBBS, PhD, FACC, Cardiologist, Department of Cardiology, Concord Hospital and Professor of Cardiology at the University of Sydney, Sydney, Australia.
The researchers tested a novel iPhone application suitable for community use (AliveCor Heart Monitor), which records and sends a high-quality single-lead ECG to a server for automated analysis and subsequent interpretation by a physician to diagnose atrial fibrillation (AF). The study included 109 patients (70 sinus rhythm and 39 AF) who had single-lead ECGs recorded with the AliveCor Heart Monitor before a 12-lead ECG had been performed, in order to develop the optimized algorithm. The AF diagnosis was then validated in another 204 patients (48 AF).
The study results indicated that a high-quality single-lead ECG can be rapidly and simply recorded using an iPhone with the AliveCor application and Heart Monitor device to accurately diagnosis AF. The results presented during the session were statistically significant with accuracy rates of 94% and 95% for the two cardiologists interpreting the raw trace, and 97% for the automated algorithm, which was optimized to enhance sensitivity (sensitivity 98%, specificity 97%).
AF is the most common sustained arrhythmia and carries a five-fold increased risk of stroke. It is common in the elderly; previously unrecognized AF is estimated to occur in 1–2% of those over 65. A significant proportion of ischemic strokes are due to previously unrecognized AF, which is largely asymptomatic, and may therefore require community screening to detect the arrhythmia.
Until now, community ECG screening has not been considered to be a feasible approach for AF detection.
Dr. Freedman concluded of the AliveCor Heart Monitor, “At last, we have an effective and simple way to do community ECG screening for unknown atrial fibrillation, with the real potential to reduce the stroke burden.”
Authors of the study include Jerrett Lau, Nicole Lowres, Lis Neubeck, David B. Brieger, Raymond W. Sy, Concord Hospital and University of Sydney, Sydney, Australia; Connor Galloway, David E. Albert, AliveCor, Oklahoma City, OK; Ben Freedman, Concord Hospital and University of Sydney, Sydney, Australia.
The AliveCor Heart Monitor, awaiting FDA 510(k) clearance, is a clinical-quality, low-cost mobile ECG heart monitor compatible with the iPhone 4 and 4S that enables patients to monitor their heart health anywhere, at any time, and provides physicians with an additional heart health assessment tool. The device and corresponding app allow for wireless recordings of rhythm strips of any duration, which are stored on the iPhone and securely in the cloud for later analysis, sharing and printing through AliveCor’s secure website. The ECG data is sent wirelessly to the iPhone from the Heart Monitor via AliveCor’s low-power, proprietary communication protocol (akin to Bluetooth, Wi-Fi or near field), and requires no pairing between the iPhone and the Heart Monitor.
AliveCor, a privately held company based in San Francisco, CA, is currently developing medical ECG heart monitoring devices and corresponding applications for mobile platforms. AliveCor aims to provide medical professionals, patients, and consumers worldwide with mobile-powered devices, data, and analysis to identify, prevent, and manage life-altering diseases from anywhere in the world.
The company was founded by Dr. David Albert and Australian co-founders Bruce Satchwell and Kim Barnett, who began working on the heart monitoring device in 2005, and is led by Judy Wade, President and CEO.